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Mycoplasma pneumoniae-associated mild
encephalitis/encephalopathy with a
reversible splenial lesion: report of two
pediatric cases and a comprehensive
literature review
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Abstract
Background: No literature review exists on Mycoplasma pneumoniae-associated mild encephalitis/encepharopathy
with a reversible splenial lesion (MERS).
Methods: M.pneumoniae-associated MERS cases were searched till August 2016 using PubMed/Google for English/
other-language publications and Ichushi (http://www.jamas.or.jp/) for Japanese-language publications. Inclusion
criteria were children fulfilling definition for encephalitis, M.pneumoniae infection, and neuroimaging showing
hyperintensity in the splenium of the corpus callosum (SCC) alone (type I) or SCC/other brain areas (type II).
Results: We described two children with type I and II M.pneumoniae-associated MERS. Thirteen cases found by the
search and our 2 cases were reviewed. Mean age, male/female ratio, duration of prodromal illness was 8.3 years, 1.5
and 3.5 days. The most common neurological symptom was drowsiness, followed by abnormal speech/behavior,
ataxia, seizure, delirium, confusion, tremor, hallucination, irritability, muscle weakness, and facial nerve paralysis.
Fever was the most common non-neurological symptom, followed by cough, headache, gastrointestinal symptoms,
headache, lethargy and dizziness. Seizure and respiratory symptoms were less common. All were diagnosed for M.
pneumoniae by serology. Cerebrospinal fluid (CSF) M.pneumoniae was undetectable by PCR in the 3 patients. Three
patients were clarithromycin-resistant. Leukocytosis, positive C-reactive protein, hyponatremia, CSF pleocytosis and
slow wave on electroencephalography frequently occurred. All except 2 were type I MERS. Neuroimaging
abnormalities disappeared within 18 days in the majority of patients. All type I patients completely recovered within
19 days. Two type II patients developed neurological sequelae, which recovered 2 and 6 months after onset.
Conclusions: Prognosis of M.pneumoniae-associated MERS is excellent. Type II MERS may increase a risk of
neurological sequelae.
Keywords: Encephalitis, MERS, Neuroimaging, Mycoplasma pneumoniae, Splenium of the corpus callosum
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Background
Clinically mild encephalopathy/encephalitis with a revers-
ible splenial lesion (MERS) is a clinicoradiological entity
with varied etiologies, characterized by a reversible lesion
with homogeneously reduced diffusion in the corpus
callosum, and often associated with symmetrical white
matter lesions on neuroimaging [1]. The most common
causes of MERS in children are infections, including rota-
virus and influenza virus [2–4]. According to the findings
on neuroimaging, MERS is classified into type I involving
solitary hyperintensity lesions in the splenium of the cor-
pus callosum (SCC) and type II involving hyperintensity
lesions in the SCC and other brain areas [5]. In general,
the most common neurological symptom in type I MERS
with varied etiologies has been reported to be delirious
behavior, followed by consciousness disturbance, and sei-
zures, all of which completely recover within a month [1].
Mycoplasma pneumoniae (M.pneumoniae) is a major
cause of community-acquired pneumonia (CAP), account-
ing for 15–20 % of CAP cases in adults and up to 40 % of
cases in children, especially in those aged 5–14 years [6].
M.pneumoniae-associated encephalitis is a common cause
of encephalitis in children, occurring in 0.1 cases per
100,000 populations of ≤19 years of age and in 3.2–
7.0 % of patients with M.pneumoniae infection [7–10],
of which up to 64 % of cases have neurological sequelae
[8, 9]. However, M.pneumoniae-associated MERS occa-
sionally occurs in children, and thus clinical features
including neurological symptoms in M.pneumonia-
associated MERS remain unknown.
Here, we describe two pediatric cases of type I and II
M.pneumoniae-associated MERS. To the best of our
knowledge, the latter case of type II MERS is the first case
of M.pneumoniae-associated MERS showing the hyperin-
teensity lesions in the SCC and the cerebellum. Currently,
there is no comprehensive review on M.pneumoniae-asso-
ciated MERS, and the difference in clinical features, neu-
roimaging findings, and outcome between type I and II
MERS remains elusive. In the present study, pediatric
cases of M.pneumoniae-associated MERS reported in the
literature were searched, and a total of cases including our
cases were reviewed to clarify clinical features, neuroimag-
ing and outcome of the disease.
Methods
Literature search
A literature search for pediatric cases of M.pneumoniae-
associated MERS was conducted from November 2004
till August 2016 using PubMed and Google Scholar data
base for Chinese-, Croatian-, Czech-, Danish-, English-,
French-, German-, Hungarian-, Italian-, Korean-, Polish-,
Portuguese-, Russian-, Spanish-, and Turkish-language
publications as well as using Ichushi Web data base (http://
www.jamas.or.jp/) for Japanese-language publications. The
search was performed using the following full keywords;
‘Mycoplasma pneumoniae’, ‘encephalitis’, ‘encephalopathy’,
‘magnetic resonance imaging’, ‘mild encephalitis/encephal-
opathy with a reversible splenial lesion’, ‘neuroimaging’ and
‘splenium of the corpus callosum’. Pediatric cases of
M.pneumoniae-associated MERS reported in the literature
and our recent cases were reviewed to clarify its clinical
and demographic features, the findings on neurological
imaging, and outcome. This study has been approved by
the ethical committee of our institution.
Selection criteria for case reports
Case reports were eligible and included in the analysis
when they met the following inclusion criteria. Chil-
dren ≤15 years of age who fulfilled; 1) the clinical
definition for acute encephalitis [9], 2) the diagnosis of
M.pneumoniae infection was confirmed by either sero-
logic tests or PCR (polymerase chain reaction) assay
for detection of M.pneumoniae, 3) the etiological case
definition for acute encephalitis caused by M.pneumo-
niae, namely, “confirmed” (detection of M.pneumoniae
by PCR in cerebrospinal fluid (CSF) or of intrathecal
synthesis of specific antibodies), “probable” (≥4-fold
rise in specific serum antibody titer using paired serum
samples), or “possible” (detection of M.pneumoniae by
PCR in throat swab specimens and/or single increased
specific serum antibody titer), were considered cases
[9], 4) the brain MRI revealed hyperintensity lesions in
the SCC alone (type I) or in the SCC and other brain
areas (type II) [5], and 5) data for demographic and
clinical characteristics were reported.
Data extraction
The following variables were extracted: patient cha-
racteristics (e.g., age, sex), acute neurological and
non-neurological symptoms, duration of prodromal non-
neurological symptoms prior to the onset of neurological
symptoms, presence or absence of macrolide (clarithro-
mycin) resistance defined by the absence of defervescence
within 72 h after initiation of clarithromycin [11], labora-
tory data, including white blood cell (WBC) count in the
peripheral blood, serum levels of C-reactive protein (CRP)
and sodium, presence or absence of pleocytosis in CSF,
findings on electroencepharography (EEG), initial and
follow-up neuroimaging, duration till recovery of clinical
symptoms and of abnormal findings on neuroimaging,




A previously healthy 14-year-old boy with a 4-day history
of fever and cough was referred to our hospital due to
clinical deterioration despite clarithromycin treatment. He
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had no remarkable medical or drug history. On admission
(day 1), he was alert without any neurological abnormal-
ities. Laboratory investigations revealed normal WBC
count (7,680/μL; normal range; 3,400-10,000/μL), normal
blood urea nitrogen (11 mg/dL, normal range; ≤21 mg/
dL), slightly elevated serum creatinine (1.03 mg/dL, nor-
mal range 0.6-1 mg/dL), hyponatremia (134 mEq/L; nor-
mal range; 135–145 mEq/L), and positive CRP (3.4 mg/
dL; normal range; <0.3 mg/dL). Serum levels of calcium,
magnesium, glucose and the liver function test were
normal. Serum anti-M.pneumoniae IgM antibody using a
rapid enzyme immunoassay (EIA, Immunocard® Myco-
plasma, Meridian Bioscience Inc., OH, USA) was negative.
Antigens of influenza virus and adenovirus in the throat
swab specimens were negative. Urinalysis was normal.
Analysis of CSF was not performed.
A chest X-ray revealed dense infiltration in the bilateral
lower lobes, indicative of pneumonia. Intravenous mino-
cycline (100 mg/day) was administered for the treatment
of M.pneumoniae pneumonia. In the following evening,
he became afebrile but developed abnormal speech and
hallucinations. In the morning on day 3, he suddenly
developed delirious behavior followed by drowsiness.
Glasgow Coma Scale (GCS) score was 8 (E3, V1, M4).
The brain MRI revealed hyperintensity lesions in the SCC
on diffusion- and T2-weighted images (Fig. 1a and b).
Intravenous dexamethasone and acyclovir were adminis-
tered. He rapidly improved and was fully conscious in the
evening on day 3. Neuroimaging on day 7 revealed dis-
appearance of hyperintensity lesions in the SCC
(Fig. 1c and d). Laboratory investigations revealed
negative CRP, while seroconversion of serum anti-M.pneu-
moniae IgM antibody was noted. He was discharged with-
out neurological sequelae on day 7.
Case 2
A previously healthy 8-year-old girl with 1-day history of
cough, headache, fever, lethargy, vomiting and diarrhea
followed by drowsiness and seizures for ~20 s was re-
ferred to our hospital. She had no remarkable medical or
Fig. 1 The brain magnetic resonance imaging (MRI) in case 1. The brain MRI on day 3 after admission revealed high intensity lesions (arrows) in
the splenium of the collupus callosum (SCC) on diffusion- (a) and T2- weighted images (b), which disappeared on day 7 (c and d)
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drug history. On the same day, her younger brother was
admitted to our hospital because of pneumonia due to
M.pneumoniae diagnosed by pulmonary manifestation,
chest X-ray finding, and positive M.pneumoniae-specific
IgM. On admission (day 1), she was drowsy; GCS score
was 8 (E3, V1, M5). Her body temperature was 38.3 °C,
and the blood pressure was normal (108/68 mmHg).
Physical examination revealed neither nuchal rigidity nor
neurological abnormalities. Laboratory investigations re-
vealed that WBC count (6,480/μL), serum levels of CRP,
calcium, magnesium, glucose, the liver function test and
urinalysis were within the normal range. However, hypo-
natremia (132 mEq/L) and positive serum anti-M.pneu-
moniae IgM antibody were noted. Serum IgM antibody
against Epstein-Barr virus capsid antigen was negative but
IgG antibody was positive, indicative of previous infection.
Antigens of influenza virus and adenovirus in the throat
swab specimens, and those of rotavirus, norovirus and
adenovirus in the stool specimens were negative. Stool
culture revealed no pathogenic bacteria. Analysis of CSF
was not performed.
A chest X-ray revealed increased bronchial markings
in the right lower lobe. The brain computed tomography
(CT) and the EEG revealed no abnormalities. Intraven-
ous fluid therapy was immediately given, followed by
administration of an anticonvulsant, diazepam supposi-
tory (6 mg), for prophylaxis of further convulsions. Six
hours later, her consciousness was fully recovered. On
the following day, she started receiving oral minocycline
(2 mg/kg/day). On day 5, she suddenly developed head-
ache, drowsiness, ataxia and intension tremor. The brain
MRI revealed hyperintensity lesions in the SCC (Fig. 2a)
and the left cerebellum (Fig. 2b) on diffusion-weighted
images. Similar signal characteristics were noted in the
SCC and the left cerebellum on T2-weighted images.
Oral minocycline was switched to intravenous adminis-
tration for additional 3 days. On day 6, she became afebrile,
rapidly improved, and was fully conscious without disturb-
ance of gait, cognition, speech, swallowing and vision.
However, she still had intension tremor, slight muscle
weakness and disabled fine motor incoordination of the left
hand. Neuroimaging on day 12 revealed disappearance of
Fig. 2 The brain MRI in case 2. The brain MRI on day 5 revealed high intensity lesions (arrows) in the SCC (a) and the left cerebellum (b) on
diffusion-weighted images, which disappeared on day 12 (c and d)
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the hyperintensity lesions in the SCC and the left cere-
bellum (Fig. 2c and d). She was discharged on day 14
with slight disability of fine motor incoordination of the
left hand, which completely recovered 2 months after
the onset of the disease.
Litterature review
The literature search found 13 cases, including 4 English-
language full reports (7 cases) [5, 12–14], 1 Japanese-
language full report (1 case) [15] and 5 Japanese-language
abstract-only reports (5 cases) [16–20]. Our recent 2 cases
described above were added for a total of 15 cases with
M.pneumoniae-associated MERS. Of the 15 patients, 5
and 10 patients were “probable” and “possible” cases,
respectively, while none was “confirmed” case. Demo-
graphic, clinical characteristics, laboratory data, neuro-
imaging findings, and outcome of these patients are
summarized in Table 1. Mean age, male/female ratio,
and mean duration of prodromal illness before the
onset of neurological symptoms were 8.3 years (range
2–14 years), 1.5 (9/6), and 3.5 days (range 1–8 days),
respectively. Of note, mean period of prodromal illness
before the onset of neurological symptoms was shorter
in the patients with type II MERS (1 day) than in those
with type I MERS (3.8 days, range 1–8 days).
As neurological symptoms, drowsiness (12/15, 80 %)
was the most common, followed by abnormal speech (5/
15, 33 %), ataxia (4/15,27 %), seizure (4/15,27 %), delirium
(3/15, 20 %), abnormal behavior (2/15,13 %), confusion (2/
15,13 %), tremor (2/15, 13 %), irritability (2/15,13 %),
hallucination (1/15,7 %), muscle weakness (1/15, 7 %),
motor deterioration (1/15, 7 %), and peripheral facial
nerve paralysis (1/15, 7 %). Among non-neurological
symptoms, fever (14/15, 93 %) was the most common,
followed by cough (8/15, 53 %), headache (7/15, 47 %),
gastrointestinal symptoms (abdominal pain, vomiting and
diarrhea, 6/15, 40 %), lethargy (5/15, 33 %), and dizziness
(1/15, 7 %). Prolonged fever (≥6 days) developed in 58 %
(7/12) of the patients, in whom the information of dur-
ation of fever was available. Seven (47 %) of the 15 pa-
tients had no respiratory symptoms.
All patients were diagnosed by serologic tests. Eight
(53 %) of the 15 patients were diagnosed by a single
measurement of M.pneumoniae-specific antibody; there
were 4 and 2 cases with positive IgM antibody as mea-
sured by EIA and enzyme-linked immunosorbent assay
(ELISA), respectively, and in the remaining 2 patients,
M.pneumoniae-specific antibody as measured by ELISA
was positive but what type of antibody was unknown. Of
these 8 patients with positive M.pneumoniae-specific
antibody, 2 patients simultaneously showed positive
M.pneumoniae DNA in the throat swab specimens by
PCR. There was a 4-fold or more rise in serum anti-
M.pneumoniae antibody titer as measured by
complement fixation test (CFT) in 1 case and by particle
agglutination assay (PA) in 4 cases. Information of the
method for serologic tests was not available in the
remaining 2 cases. None of the patients underwent cul-
ture analysis.
Three patients showed clarithromycin resistance. Chest
X-ray or CT of the 7 patients examined revealed infiltra-
tion of the lobes (n = 5) or increased bronchial markings
(n = 2). Leukocytosis (>10,000 WBCs/μL), positive CRP
(>0.3 mg/dL) and hyponatremia (<135 mEq/L) were noted
in 42 % (5/12), 75 % (9/12) and 44 % (4/9) of the patients,
respectively. CSF pleocytosis (>10WBCs/μL) was found in
3 (33 %) of the 9 patients, three of whom showed negative
M.pneumoniae in CSF as measured by PCR. The levels of
interleukin (IL)-6 in CSF were elevated in a patient with
type I MERS. EEG revealed slow wave in 63 % (5/8) of the
patients examined.
On neuroimaging, all except 2 patients showed type I
MERS. Two patients were type II MERS; our case 2 with
hyperintensity lesions in the SCC and the left cerebellar
lesions, and other case with those in the SCC, center
semiovale and parietal white matter bilaterally [5].
Hyperintensity lesions in the SCC and other brain areas
on neuroimaging disappeared within 18 days in all
except 4 patients including 3 with type I and 1 with type
II MERS, in whom the lesions on the follow-up MRI
disappeared 2–4 months after the initial MRI.
Antibiotic treatment included azithromycin (4/10), cipro-
floxacin (3/10), and minocycline (3/10), while none re-
ceived clarithromycin after the onset of MERS. Intravenous
steroids were given to 42 % (5/12) of the patients. All
patients with type I MERS completely recovered within
19 days, while 2 patients with type II MERS developed
neurological sequelae, which recovered 2 and 6 months,
respectively, after the onset of the disease.
Discussion
There is some concern about the diagnostic tests for
acute M.pneumoniae infection. Culture is impractical
since the long time is required to get the results [21].
Serologic tests have been most widely used and a 4-fold
rise in antibody titer in acute and convalescent sera is
considered the “gold standard”. However, the use of a
single qualitative measurements of IgM has low sensitiv-
ity (32–77 %)[22, 23], which increases (88.6 %) when
paired sera are analysed [23]. Taking sera during both
phases is too late for point-of-care diagnosis and difficult
in children [22]. False-positive results occur since IgM
remains detectable for several months following infec-
tion [21, 22]. False-negative results occur when serum is
collected within 7 days after onset [21, 22] and in im-
munocompromised patients and infants <6 months of
age, who often do not produce IgM [21]. PCR is highly
sensitive and measures blood, CSF, and pharyngeal
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samples. False positive results occur due to colonization
and prolonged shedding from previous infection [22].
False-negative results occur due to contamination, in-
hibitors in samples, or timing of sample collection [22].
Thus, the combination of PCR plus serology yields the
most reliable results. Despite inadequate validity of
serology and untested other respiratory pathogens,
pulmonary symptoms, chest X-ray findings, IgM sero-
conversion and interfamilial M.pneumoniae infection
episode strongly suggest that our cases are considered
“possible” cases.
All except one case [5] were reported from Asia;
Japan [12, 15–20] and China [13, 14], suggesting a
role of racial factor(s) for M.pneumoniae-associated
MERS. As M.pneumoniae-associated encephalitis [7–10],
M.pneumoniae-associated MERS predominantly occurs in
children aged 2–14 years. Adult case of M.pneumoniae-
associated MERS was only reported [24]. Thus, young age
may be a predisposing factor of M.pneumoniae-associated
MERS. As M.pneumoniae-associated encephalitis [9] and
MERS by other causes [14], male preponderance is noted
in M.pneumoniae-associated MERS.
Extrapulmonary complications, in particular encephal-
itis, occurred more frequently in children with macrolide-
resistant than in those with macrolide-sensitive
M.pneumoniae [25]. However, our study suggested
that clarithromycin resistance is not a predisposing
factor of M.pneumoniae-associated MERS.
Table 1 Pediatric cases of MERS associated with Mycoplasma pneumoniae infection





















NA IgMAb/CFT probable NA NA 7,950
3 F 3 Drowsiness, seizure Diarrhea, fever,
vomiting
6 IgMAb/EIA possible NA NA normal
8 M 2 Ataxia, confusion,
drowsiness
Fever, lethargy 6 IgMAb/EIA possible NA NA increased






MP (+) in PS
by PCR
possible NA NA 4,500




MP (+) in PS
by PCR
possible NA IF 8,100





2 ELISA possible NA NA 11,600




4 ELISA possible NA NA 12,600
6 M 6 Drowsiness, irritability Cough, fever,
headache
10 PA probable + IBM 11,800
8 F 1 Ataxia, muscle
weakness, tremor
Cough, fever NA PA probable NA IF 8,000
10 F 1 Drowsiness Cough 0 PA probable NA IF NA
12 F 7 Abnormal behavior,
drowsiness, seizure
Fever NA NA possible NA NA NA
6 F 4 Delirium Cough, fever 8 NA possible + IF NA




6 PA probable NA NA 16,400





5 IgMAb/EIA possible + IF 7,680





9 IgMAb/EIA possible NA IBM 6,480
Ab antibody, Abd abdominal, AZT azithromycin, CFT complement fixation test, CIP ciprofloxacin, CR complete recovery, CRP C-reactive protein. CSF cerebrospinal
fluid, CT computed tomography, EEG electroencephalography, EIA enzyme immunoassay, ELISA enzyme-linked immusorbent assay, IBM increased bronchial
markings, IF infiltration, IL interleukin, MINO minocycline, MERS mild encephalitis/encephalopathy with a reversible splenial lesion, MP Mycoplasma pneumoniae, MR
macrolide (clarithromycin) resistance, MRI magnetic resonance imaging, PA particle agglutination assay, PCR polymerase chain reaction, PS pharyngeal swab
sample, SCC splenium of the corpus callosum, SW slow wave, WBC white blood cell. ↑ increase, ND not done, NA not available
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Disturbance of consciousness, delirious behavior
and ataxia are common neurological symptoms in
M.pneumoniae-associated MERS as MERS by other
causes [3, 26]. In contrast to M.pneumoniae-associated en-
cephalitis (48–67 %) [8, 27, 28], seizure is less common
(27 %) in MERS due to M.pneumoniae as that by other
causes (14–32 %) [3, 26], probably due to mild brain dys-
function in M.pneumoniae-associated MERS. This is sup-
ported by the EEG finding; normal to mild abnormality (i.e.
slow wave) as in MERS by other causes [26] versus diffuse
cortical dysfunction and focal epileptiform discharge in
M.pneumoniae-associated encephalitis [27, 29]. It remains
unknown how the SCC lesions cause neurological manifes-
tations. The splenium is the posterior part of the corpus
callosum, connecting different cortical areas, including oc-
cipital, parietal and temporal lobes [30]. Thus, the lesions in
the SCC and other brain regions connecting SCC lead to
various neurological manifestations [31]. Neuroimaging
findings in type II MERS suggests that neurological symp-
toms in MERS may be due to the lesions in both the SCC
and other brain regions connecting the SCC.
Fever is the most common non-neurological symptom
as in M.pneumoniae-associated encephalitis [7–10, 29].
Prolonged fever (≥6 days) is noted in the majority of the
patients, while respiratory symptoms are less common
(47 %) as in M.pneumoniae-associated encephalitis
(~44 %) [7, 32]. Longer intervals between respiratory
and CNS manifestations were associated with worse out-
come in M.pneumoniae-associated encephalopathy [33].
However, short intervals in type II M.pneumoniae-as-
sociated MERS suggest that short period of pro-
dromal illness before the onset of CNS manifestations
may predict severe MERS as in M.pneumoniae-associ-
ated encephalitis [8].
Leukocytosis and positive CRP were associated with
severe M.pneumoniae infection [34]. Prevalence of
leukocytosis and positive CRP in the patients reported
here is similar to that (57 and 71 %, respectively) in MERS
by other causes [3]. Our and other cases of type II MERS
[5] showed no leukocytosis and negative CRP, suggesting
no predictive values of these parameters for worse out-
come. Our study showed that CSF pleocytosis occurs more
frequently in M.pneumoniae-associated MERS (33 %) than
in MERS by other causes (0 %) [3], and its prevalence is
similar to that (33–66 %) in M.pneuminiae-associated en-
cephalitis [8, 29, 35]. In contrast to M.pneumoniae-associ-
ated encephalitis [35], CSF pleocytosis does not seem to
increase a risk of neurological sequelae or worse outcome.
Table 1 Pediatric cases of MERS associated with Mycoplasma pneumoniae infection (Continued)






(mg/dl) (mEq/L) finding findings Antibiotics Steroids
13 0.1 NA pleocytosis SW type II, SCC,
center semiovale,
genu, parietal
90 180 CIP – CR [5]
3 – NA normal NA type I 60 3 AZT – CR [12]
8 + NA normal NA type I 6 8 AZT + CR [12]
9 1.6 127 normal
MP (−) in
CSF by PCR
SW type I 7 10 AZT – CR [13]




SW type I 3 8 AZT – CR [13]
2 6.6 136 normal normal type I 120 8 NA – CR [14]
6 16.8 135 normal SW type I 67 19 NA + CR [14]
6 0.33 135 pleocytosis SW type I 18 12 CIP – CR [15]
8 5.72 136 ND NA type I 8 8 NA NA CR [16]
10 NA NA ND NA type I 15 4 NA NA CR [17]
12 NA NA NA NA type I NA 10 NA + CR [18]
6 NA NA ND NA type I 11 8 CIP NA CR [19]
7 1.1 131 pleocytosis
MP (−) in CSF
by PCR
normal type I 4 4 MINO + CR [20]
14 2.6 134 ND ND type I 7 7 MINO + CR Case1
8 <0.3 133 ND normal type II,SCC,
left cerebellum
7 60 MINO – CR Case2
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The mechanism by which the SCC lesions occur in
MERS remains elusive. Hyponatremia has been pro-
posed to reduce the intracellular osmotic pressure in the
SCC, leading to transient edema [36]. Hyponatremia
exacerbates the SCC injury [37]. However, hyponatremia
occurs in less than a half of M.pneumoniae-associated
MERS patients, similar to MERS by other causes (37–83 %)
[3, 14, 26, 36, 38], suggesting that hyponatremia may be a
modulator but not essential for development of the SCC le-
sions. As M.pneumoniae-associated encephalitis [7, 9, 33],
PCR rarely detected M.pneuminiae in CSF of M.pneumo-
niae-associated MERS [13, 20], suggesting indirect mecha-
nisms such as immune-mediated mechanism [1] rather
than direct invasion of M.pneumoniae, leading to the SCC
lesions. The levels of CSF IL-6 were increased in MERS
due to M.pneumoniae [13] and other causes [39]. IL-6
induces the SCC injury [40]. An oxidative stress marker in
CSF was increased in MERS by other causes [39]. Low
levels of glutathione reductase, anti-oxidant enzyme, in the
corpus callosum [41] make the SCC more susceptible to
oxidant injury. Proinflammatory cytokines, oxidants and
reduced anti-oxidant enzymes may lead to the SCC lesions.
Anti-N-methyl-D-aspartate receptor (NMDAR) antibody
was detected in serum and CSF of M.Pneumoniae-associ-
ated encephalitis [42]. NMDARs are expressed in the SCC
[43]. Thus, anti-NMDAR antibody may be a potential con-
tributing factor to the SCC lesions [44].
M.pneumoniae-associated MERS is type I in almost all
patients, while 2 (13 %) patients developed type II MERS
[5] including our case. In type I MERS by other causes,
hyperintensity lesions in the SCC disappeared 3 days to
2 months following the initial MRI and 53 % of the
patients recovered within 1 week [45]. In M.pneumoniae-
associated MERS, the neuroimaging finding normalized
~18 days after the initial MRI in all except 4 (3 type I and
1 type II) [5, 12, 14], in which it normalized 2–4 months.
As MERS by other causes (31 %) [25], intravenous
steroids were only given to 42 % of the patients. Steroids
are not essential other than treating concomitant infec-
tion partly because the natural history of M.pneumo-
niae-associated MERS is almost always excellent.
Despite high mortality (9 %) [10] and prevalence of
neurologic sequelae (18–64 %) in M.pneumoniae-asso-
ciated encephalitis [8, 10, 28], prognosis is excellent
and neurological sequelae never develop in type I M.pneu-
moniae-associated MERS. All except 2 patients with type
II MERS [5], including our case, fully recovered within
19 days after the onset. Neurological symptoms recovered
as the neuroimaging finding improved. In contrast, our
case and other case with type II MERS [5] developed
neurological sequelae, which disappeared 2 and 6 months,
respectively, after the onset, suggesting that prognosis
of M.pneumoniae-associated MERS may depend on
the extent of brain lesions affected.
Limitation of the present study includes its retrospect-
ive and observational nature, too small sample size, and
inadequate validity of diagnostic method for M.pneumo-
niae infection in reported cases.
Conclusions
MERS could be associated with M.pneumoniae infection
and M.pneumoniae-associated MERS predominantly oc-
curs in children with male preponderance. Seizure and
respiratory symptoms are less common. Despite excel-
lent outcome in type I M.pneumoniae-associated MERS,
there may be a risk of neurological sequelae in type II
MERS, depending on the brain lesions affected. Short
intervals between prodromal illness and CNS manifesta-
tions may be associated with type II MERS. Limitation
of the present descriptive and retrospective study with
small sample size warrants further investigations to clar-
ify clinical features and risk factors of MERS that could
be associated with M.pneumoniae infection.
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